Intracellular delivery and passive tumor targeting of a self-assembled nanogel containing carborane clusters for boron neutron capture therapy
- 1. JST-ERATO, Japan Science and Technology Agency (JST), The Exploratory Research for Advanced Technology (ERATO), Bio-nanotransporter Project, Katsura, Nishikyo-ku, Kyoto 615-8510 (Japan)
- 2. Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510 (Japan)
Description
Boron neutron capture therapy, based on the release of thermal neutron irradiation from boron, is a targeted radiation therapy for cancer. Targeted and sufficient accumulation of boron in tumor cells to achieve cytotoxic efficacy and reduce off-target effects remains a challenge. Carborane has been investigated for use as a delivery agent in boron neutron capture therapy because of its high boron content and chemical stability; however, it is cytotoxic, making safe delivery difficult. The aim of this study was to investigate the potential of carborane-bearing pullulan nanogels to safely and effectively deliver boron to tumor cells in vitro and in vivo and, consequently, assess their potential as a boron neutron capture therapeutic. Murine fibrosarcoma cells (CMS5a) were used for in vitro investigations of nanogel cytotoxicity, cell uptake. A mouse fibrosarcoma xenograft model was used to investigate the bio-distribution of nanogels after intravenous administration. The nanogels produced no apparent cytotoxicity and underwent cell uptake in CMS5a cells after a 24 h incubation at up to 2000 μg/mL and 400 μg/mL, respectively. The internalized nanogels were localized around the nuclear membrane. The nanogels were administered intravenously to mice bearing fibrosarcoma xenografts. Nanogel tumor localization likely occurred through the enhanced permeation and retention effect. The nanogels successfully reduced the cytotoxicity of carborane, were internalized into tumor cells, acted as a dual-delivery therapeutic and accumulated in tumors in vivo. Consequently, they demonstrate significant potential as a boron neutron capture therapeutic. - Highlights: • A carborane-bearing pullulan nanogel is developed as a boron delivery agent. • The nanogels are cell-friendly and show effective cell uptake for drug delivery. • The nanogels show passive tumor targeting by enhanced permeation and retention.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2016.12.176Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2016.12.176;
- PII
- S0006-291X(16)32248-3;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 483
- Journal Issue
- 1
- Journal Page Range
- p. 147-152
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 49046507
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- BORON; CARBORANES; IN VIVO; NEUTRON CAPTURE THERAPY; POTENTIALS; THERMAL NEUTRONS; TOXICITY; TUMOR CELLS; UPTAKE
- Descriptors DEC
- ANIMAL CELLS; BARYONS; CARBON COMPOUNDS; ELEMENTARY PARTICLES; ELEMENTS; FERMIONS; HADRONS; MEDICINE; NEUTRON THERAPY; NEUTRONS; NUCLEAR MEDICINE; NUCLEONS; ORGANIC BORON COMPOUNDS; ORGANIC COMPOUNDS; RADIOLOGY; RADIOTHERAPY; SEMIMETALS; THERAPY
Optional Information
- Copyright
- Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.